Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

医学 贝伐单抗 内科学 妇科肿瘤学 卵巢癌 耐受性 无进展生存期 不利影响 肿瘤科 危险系数 胃肠病学 外科 癌症 化疗 置信区间
作者
Robert A. Burger,Michael W. Sill,Bradley J. Monk,Benjamin E. Greer,Joel I. Sorosky
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:25 (33): 5165-5171 被引量:877
标识
DOI:10.1200/jco.2007.11.5345
摘要

Purpose Vascular endothelial growth factor (VEGF) seems to be a promoter of tumor progression for epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). We conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab, an anti-VEGF monoclonal antibody. Patients and Methods Eligible patients had persistent or recurrent EOC/PPC after one to two prior cytotoxic regimens, measurable disease, and Gynecologic Oncology Group performance status of at least 2. Treatment consisted of bevacizumab 15 mg/kg intravenously every 21 days until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and clinical response. Results The study consisted of 62 eligible and assessable patients, median age 57 years, 41 (66.1%) having received two prior regimens and 36 (58.1%) considered platinum resistant. Grade 3 adverse events at least possibly related to bevacizumab were hematologic (1), GI (3), hypertension (6), thromboembolism (1), allergy (2), hepatic (1), pain (3), coagulation (1), constitutional (1), and dyspnea (1). Grade 4 adverse events included pulmonary embolus (1), vomiting and constipation (1), and proteinuria (1). Thirteen patients (21.0%) experienced clinical responses (two complete, 11 partial; median response duration, 10 months), and 25 (40.3%) survived progression free for at least 6 months. Median PFS and overall survival were 4.7 and 17 months, respectively. There was no significant association of prior platinum sensitivity, age, number of prior chemotherapeutic regimens, or performance status with the hazard of progression or death. Conclusion Bevacizumab seems to be well tolerated and active in the second- and third-line treatment of patients with EOC/PPC and merits phase III investigation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wkw发布了新的文献求助10
刚刚
bkagyin的应助被不想看文献采纳,获得10
1秒前
归途完成签到,获得积分10
4秒前
NexusExplorer的应助被zhangxinyi采纳,获得10
4秒前
周周发布了新的文献求助10
4秒前
科研通AI65的应助被ad采纳,获得10
4秒前
6秒前
Mickey完成签到 ,获得积分10
6秒前
abcd_1067完成签到,获得积分10
6秒前
不安的恶天完成签到,获得积分10
6秒前
顾矜的应助被小y同学采纳,获得10
6秒前
6秒前
minmin完成签到 ,获得积分10
7秒前
在水一方的应助被Eana采纳,获得10
8秒前
8秒前
8秒前
妮妮完成签到,获得积分10
8秒前
9秒前
大个的应助被科研通管家采纳,获得10
9秒前
Cr的应助被科研通管家采纳,获得10
9秒前
科研通AI2S的应助被临平吴彦祖采纳,获得10
9秒前
CipherSage的应助被科研通管家采纳,获得10
9秒前
sendou的应助被科研通管家采纳,获得30
9秒前
Jasper的应助被科研通管家采纳,获得10
9秒前
10秒前
yn107发布了新的文献求助10
10秒前
顾矜的应助被科研通管家采纳,获得10
10秒前
科研菜菜的应助被科研通管家采纳,获得30
10秒前
Eric完成签到,获得积分10
10秒前
10秒前
wanci的应助被科研通管家采纳,获得10
10秒前
英俊的铭的应助被科研通管家采纳,获得10
10秒前
上官若男的应助被科研通管家采纳,获得10
10秒前
脑洞疼的应助被科研通管家采纳,获得10
11秒前
Akim的应助被科研通管家采纳,获得10
11秒前
所所的应助被科研通管家采纳,获得10
11秒前
11秒前
Jasper的应助被科研通管家采纳,获得10
11秒前
Cr的应助被科研通管家采纳,获得10
11秒前
思源的应助被科研通管家采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183508
求助须知:如何正确求助?哪些是违规求助? 9572862
关于积分的说明 21827639
捐赠科研通 7780681
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480405